To the Editor. —
We would like to elaborate on one point of the excellent article "Therapeutic Strategies Against Tardive Dyskinesia" by Jeste and Wyatt (Archives 1982;39:803-816). The authors classified bromocriptine mesylate as a treatment of dopamine (DA) antagonism, ie, decreasing DA neurotransmission. This may not be entirely accurate for the three studies cited.1-3 Although the use of an "autoreceptor strategy" in the treatment of tardive dyskinesia (TD) with DA agonists has been described,1 in the case of bromocriptine this probably was never effected. This strategy was based on the belief that bromocriptine binds preferentially at different DA receptor sites in different concentrations.1,4 However, in view of the fact that multiple classes of DA receptors exist in the nigrostriatal system, which is believed to be the critical neuroanatomic area in TD, and that the oral dosage of bromocriptine required to obtain precisely the desired pharmacodynamic effect
Lieberman J, Lesser M, Brenner R. Is Bromocriptine a Dopamine Antagonist Treatment?. Arch Gen Psychiatry. 1983;40(4):469–470. doi:10.1001/archpsyc.1983.01790040123023
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: